The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking by Peterson, Laura B. et al.
The hERG channel is dependent upon the Hsp90α isoform for
maturation and trafficking
Laura B. Peterson1, Jeffrey D. Eskew2, George A. Vielhauer2,3, and Brian S. J. Blagg1
1Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive,
Lawrence, KS, 66045, USA
2Department of Urology, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas
City, KS, 66160, USA
3The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901
Rainbow Blvd, Kansas City, KS, 66160, USA
Abstract
Heat shock protein 90 (Hsp90) has emerged as a promising therapeutic target for the treatment of
cancer. Several Hsp90 inhibitors have entered clinical trials. However, some toxicological
detriments have arisen, such as cardiotoxicity resulting from hERG inhibition following the
administration of Hsp90 inhibitors. We sought to investigate this toxicity as hERG has been
previously reported as a client protein that depends upon Hsp90 for its maturation and functional
trafficking. In this study we show that hERG depends upon a single Hsp90 isoform. hERG
preferentially co-immunoprecipitated with Hsp90α and genetic knockdown of Hsp90α, but not
Hsp90β, resulted in a trafficking-defective hERG channel. This study demonstrates the importance
of delineating the isoform dependence of Hsp90 client proteins and provides rationale for the




The 90-kDa heat shock protein (Hsp90) is an abundant molecular chaperone intimately
involved in protein folding, activation, and stabilization. Hsp90 client proteins, those that
rely on Hsp90 for their activity, include important signaling molecules, transcription factors,
hormone receptors and kinases. Many of these client proteins are intimately involved in
oncogenic progression, providing rationale for the development of Hsp90 inhibitors as a
promising therapeutic strategy for the treatment of cancer.1 Several Hsp90 inhibitors have
entered clinical trials; however, results from these trials have been somewhat disappointing.
In many cases, clinical candidates have been plagued by a lack of efficacy, hepatotoxicity,
cardiotoxicity or manifested detrimental off-target effects.2-3 While some of these
detriments may be associated with the molecular scaffold, others may result from pan-Hsp90
inhibition, i.e. the inhibition of all Hsp90 isoforms.
In humans, there are four Hsp90 isoforms: Hsp90α and Hsp90β reside primarily in the
cytoplasm and are stress-inducible and constitutively expressed, respectively.4 Glucose
regulated protein 94 (Grp94) is localized to the endoplasmic reticulum, while tumor necrosis
factor receptor associated protein1 (Trap1) is the mitochondrial-resident chaperone.
Distinguishing the role played by each Hsp90 isoform has been a significant challenge,
especially those manifested by the two cytosolic isoforms, which are structurally very
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similar (86% identical, 93% similar).4-5 The responsibility of each cytosolic isoform appears
to overlap with some client proteins. However, recent evidence has emerged that suggests
co-chaperones and client proteins interact with each isoform in a unique manner.5 All
currently described Hsp90 inhibitors manifest pan-inhibition and since cardiotoxicity
represents a major hurdle for Hsp90 inhibitor development, we investigated whether the
hERG channel was an isoform-dependent Hsp90 client protein.
The α-subunit of the voltage gated potassium channel, the human ether-a-gogo-related gene
product, hERG, constitutes a major component of the ion channel responsible for
repolarization of cardiac action potential.6-7 Ficker et al. demonstrated previously that hERG
depends upon Hsp90 for its functional maturation and that pharmacological inhibition of
Hsp90 had deleterious effects on the hERG-related membrane potential.8-9 Defects in the
hERG channel or off-target pharmacological inhibition of the hERG channel can cause long-
QT syndrome, resulting in ventricular arrhythmias and even death.7,10 There are three
primary classes of compounds that disrupt hERG function; 1) compounds that bind directly
to and inhibit the hERG channel (hERG blockers), 2) compounds that inhibit the functional
trafficking of hERG, or 3) compounds that exhibit both hERG blocking and hERG
trafficking inhibitory abilities.11-12 Hsp90 inhibitors have been shown to disrupt hERG
function and cause a reduction in hERG-related membrane currents in in-vitro studies. It has
previously been demonstrated that the Hsp90 inhibitor, geldanamycin, inhibits hERG
trafficking, presumably through an Hsp90-dependent mechanism.8 Given the intense
pharmaceutical interest in the development of Hsp90 inhibitors as therapies for cancer and
other diseases, the importance of identifying the isoform dependency of this client protein is
clear, as pan-inhibition may result in undesired effects.
Experimental Section
Antibodies
The following antibodies were used for Western Blotting and/or co-immunoprecipitation:
rabbit anti-Hsp90α (Neomarkers), goat anti-Hsp90β (SantaCruz), goat anti-hERG
(SantaCruz), rabbit anti-Grp94 (SantaCruz) and rabbit anti-Actin (SantaCruz).
Cell Lines
The HEK-hERG13 (HEK 293 stably transfected with human hERG WT) cell line was a kind
gift from Eckhard Ficker (MetroHealth Medical Center/Case Western Reserve University).
The HEK-hERG cell line was maintained in DMEM supplemented with 10% FBS,
streptomycin, penicillin, and geneticin at 37°C, 5% CO2. Inducible knockdown of Hsp90α
or Hsp90β in the HEK-hERG cell line was accomplished using a tetracycline inducible
shRNA construct containing a hairpin sequence specific for either the Hsp90α or Hsp90β
isoform. These constructs were made by subcloning the isoform specific hairpin sequences
from pGIPZ vectors (Open Biosystems, Lafayette, CO) into pTRIPZ vectors using MluI and
XhoI restriction sites. The mature shRNA sequences were 5′–
AGGAAGAATTTGGTCAAAA–3′ and 5′–ACTAAGAAGATCAAAGAGA–3′ for
Hsp90α and Hsp90β respectively. Resulting clones where sequenced verified using pTRIPZ
sequencing primers 5′–GGAAAGAATCAAGGAGG3′. The resulting pTRIPZ plasmids
containing Hsp90 isoform specific shRNA were packaged into third generation lentivirus
particles. Cells were cultured as above but with the addition of 2.5 μg/mL puromycin to
select for stable, transduced cells. Induction of shRNA expression with tetracycline dose
was monitored by the increase in TurboRFP fluorescence which is driven by the tetracycline
response element (TRE). shRNA expression was induced with the addition of 1-24 μg/mL
doxycyline.
Peterson et al. Page 2














Cells were plated in 24-well plates at 9.0×105 cells/mL (0.5 mL/well) in antibiotic free
DMEM supplemented with 10% FBS. After 24 h., media was replaced with 0.2 mL
OptiMEM (Invitrogen) and transfected with 43 uL of transfection mix containing 50 pmol
siRNA and 2 uL oligofectamine (Invitrogen). Proteins were harvested 48 h. post
transfection. Hsp90α siRNA was purchased from Ambion while Hsp90β siRNA was from
SantaCruz Biotechnology.
Western Blot Analysis
The various HEK cells were harvested in cold PBS and lysed in mammalian protein
extraction reagent (MPER, Pierce) lysis buffer containing protease inhibitors (Roche) on ice
for 1 h. Lysates were clarified at 14,000g for 10 min at 4° C. Protein concentrations were
determined using the Pierce BCA protein assay kit per the manufacturer’s instructions.
Equal amounts of protein (2.5-10 μg) were electrophoresed under reducing conditions (6.5%
acrylamide gel), transferred to a polyvinylidene fluoride membrane (PVDF), and
immunoblotted with the corresponding specific antibodies. Membranes were incubated with
an appropriate horseradish peroxidase-labeled secondary antibody, developed with a
chemiluminescent substrate, and visualized.
Immunoprecipitation
Using a method analogous to Ficker et al.8 and Nanduri et al.9, cells were plated in 10 cm
cell culture dishes and allowed to grow to 80% confluency. Cells were then washed once
with phosphate-buffered saline (PBS) and then crosslinked by incubation with 1.5 mM
dithiobis(succinimidyl propionate, DSP, Pierce) in PBS for 15 min at room temperature.
DSP was quenched by the addition of pH 7.5 Tris (final concentration 10 mM). Cells in
PBS/DSP/Tris were scraped into conical tubes, pelleted, and washed with PBS. Cells were
harvested in lysis buffer containing 0.1% NP40, 50 mM Tris (pH 7.5), 150 mM NaCl, 20
mM MoO4, and protease inhibitors (Roche). Lysates were clarified and protein
concentration was determined using BCA assay. For co-immunoprecipitation, 300 ug total
protein was diluted to 500 uL total volume in lysis buffer and incubated with 2μg of either
anti-hERG, anti-Hsp90α or anti-Hsp90β antibody overnight at 4°C with rocking.
Immunocomplexes were captured with 35μL of DynaBeads Protein G (Invitrogen) for 2 h.
with rocking at 4°C. Protein G Bead-complexes were washed three times with lysis buffer
and eluted with sample buffer. Samples were then boiled and subjected to SDS-PAGE and
Western Blot analysis.
Tryptic Digest and Mass Spectrometry
Lysates were co-immunoprecipitated as above except with 1 mg total protein, 6 ug anti-
hERG antibody, and 100 μL DynaBeads Protein G in 1.5 mL total volume. After wash
steps, samples were boiled and subjected to SDS-PAGE. Acrylamide gels were stained,
bands excised, destained and washed using the Silver Stain Kit for Mass Spectrometry
(Pierce). Excised bands were further washed (0.2 M NH4HCO3, 50% acetonitrile) and then
dried. Gel pieces were suspended in 0.2 M NH4HCO3 and 10 mM DTT (final concentration)
was added and heated at 60°C for 15 mins. 20 mM iodoacetamide (final concentration) was
then added and gel bands incubated for 30 mins at 25°C in the dark. Gel bands were then
washed (0.2 M NH4HCO3, 50% acetonitrile), shrunk in 100% acetonitrile, and dried. Gel
bands were re-swelled in 0.2 M NH4HCO3 containing 0.5 μg trypsin and 0.2 M NH4HCO3
with 10% acetonitrile was added to keep gel pieces submerged. Digest was terminated after
16 h. of incubation at 37°C by the addition of 0.1% trifluoroacetic acid (final concentration).
Supernatants were then subjected to LC-MS/MS at the University of Kansas Analytical
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Proteomics Lab. Results were analyzed using Scaffold software which integrates results
from Mascot, Sequest and X!Tandem search engines.
Densitometry and Statistical Analysis
Western Blot films were digitally captured using a standard flatbed scanner (HP). The
digital blots were then converted to 16-bit black and white images using ImageJ software.
Densitometric measurements were then performed in ImageJ using the “Gels” tool. Peak
areas were used as a measure of protein levels. Statistical analysis was performed using
GraphPad Prism5, statistical significance was determined using a paired, two-tailed t-test.
Results and Discussion
hERG Interacts Solely with Hsp90α
The K+ channel encoded by the human ether-a-gogo-related gene (hERG) plays a major role
in the repolarization of cardiac myocytes following normal action potential.6 Although
pharmacological inhibition of hERG itself is a therapeutic target for the treatment of some
cardiac arrhythmias, more often undesired inhibition of hERG is an off-target effect that
results in cardiotoxicity and leads to the ultimate failure of pre-clinical or clinical
candidates.7 hERG has been previously identified as an Hsp90/Hsp70–dependent client
protein, and studies have shown that inhibition of Hsp90 with geldanamycin resulted in
proteasome-mediated degradation of hERG which prevented maturation of a fully functional
hERG channel.8-9 In addition, the Hsp90 co-chaperones Hsp-organizing protein (Hop),
Hdj-2, and BCL-associated athanogene 2 (Bag-2), as well as the 38-kDa FK506 binding
protein (FKBP38) and calnexin were found to interact with hERG, presumably to aid in
hERG maturation.14 Based on these observations, we sought to determine whether hERG
was dependent upon a sole Hsp90 isoform, which would provide rationale to support the
development of Hsp90 isoform-selective inhibitors that avoid such detriments.
Using the method of Ficker et al.8 co-immunoprecipitation studies were performed to
evaluate the interaction of hERG with each of the Hsp90 isoforms. hERG expressing HEK
(HEK-hERG) cell lysates were chemically crosslinked and immunoprecipitated utilizing
antibodies that recognize Hsp90α, Hsp90β, or hERG (Figure 1). hERG channels exist as
either a functional, fully glycosylated mature form (fg) or an immature core-glycosylated
protein (cg), and both species can be detected by Western Blot analysis.15-17 As previously
determined, Hsp90 only interacts with the core glycosylated hERG (Figure 1).8 In addition,
as evidenced in Figure 1, hERG only interacts with a single Hsp90 isoform, namely
Hsp90α. The hERG-Hsp90α interaction can be captured by co-immunoprecipitation with
either an anti-hERG or anti-Hsp90α antibody (Figure 1 and data not shown).
In order to identify other proteins involved in this interaction, we performed co-
immunoprecipitations with anti-hERG antibody, separated the complexes on SDS-PAGE,
excised protein bands and subjected the proteins to tryptic digest and mass spectrometry.
Using this approach we identified Hsp90α in the hERG-associated complex. Since Hsp90α
and Hsp90β are overall 86% identical, it is important to note that we observed overlapping
peptides derived from both isoforms, however only unique peptides from Hsp90α were
identified during these studies. In addition to the chaperones and co-chaperones previously
identified to interact in the hERG complex,14 additional proteins were found (Table 1). The
Hsp/c70 co-chaperone, Hsc70-interacting protein (Hip), was found in this complex and
typically directs Hsc70 to the Hsp90 complex with the help of the Hsp organizing protein
(Hop). Two additional peptidyl-prolyl cis-trans isomerases were also identified, FK506
binding protein 51 (FKBP51) and Cyclophilin A (CypA). FKBP51 has previously been
identified in Hsp90 complexes, specifically those that contain the steroid hormone
receptors.18 Hsp90 associated immunophilins typically bind to the C-terminus of Hsp90 and
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mediate interactions between Hsp90 and other co-chaperones. CypA and Hsp90 have been
shown to be necessary for cell membrane translocation of toxins from both Bacillus
anthracis and Clostridium difficile, however, the involvement of CypA in Hsp90-mediated
client protein maturation has not been reported.19-20 Another tetratricopeptide repeat-
containing protein, 14-3-3 protein epsilon (14-3-3) was also identified. Its role in client
protein maturation is undocumented, however TPR-domain containing proteins typically
mediate protein-protein interactions.
Hsp90α and Hsp90β Knockdown have Differential Effects on hERG Trafficking
To investigate the relationship between each of the cytosolic Hsp90 isoforms and hERG
maturation, we analyzed the effects of either Hsp90α or Hsp90β knockdown using RNA
interference with siRNAs targeted to each isoform. Under control conditions (scrambled
siRNA), both the fully glycosylated and core glycosylated hERG proteins were observed
(Figure 2A). Previously, it was shown that Hsp90 inhibitors, such as geldanamycin and
radicicol, cause both a dose-dependent reduction in the hERG-associated current amplitudes
in patch clamp experiments and in the trafficking efficiency of hERG, or the ratio of fg
hERG over total hERG (fg+cg) (Figure 2B).8 Knockdown of Hsp90α (60% reduction)
caused approximately a 70% reduction in the trafficking efficiency of hERG and a 55%
reduction in the total amount of hERG (Figure 2C). Conversely, the hERG trafficking
efficiency and total amount of hERG remained unchanged after Hsp90β knockdown (60%
reduction).
For further confirmation, we sought to demonstrate a direct relationship between the amount
of functional Hsp90α and the trafficking efficiency of hERG. Using a tetracycline-induced
promoter linked to the expression of either an Hsp90α or Hsp90β targeted shRNA, this
relationship was investigated (Figure 3). Figure 3 demonstrates the direct relationship
between the amount of Hsp90α and the trafficking efficiency of the hERG channel.
Decreasing amount of Hsp90α in these cells causes a “dose-dependent” decrease in the
amount of fully glycosylated, functional hERG after both 24 and 48 hours (Figure 3A/C and
3B/D/G). In addition, we observed a reduction in the total amount of hERG (fg+cg) in these
cells following shRNA-mediated Hsp90α reduction (Figure 3 C/D). Conversely, reduction
in the amount of Hsp90β had no effect on the glycosylation state, i.e. functional activity, or
total hERG (Figure 3A/E and 3B/F/H). These data further demonstrate the isoform
dependent nature of the hERG channel for Hsp90α.
As pharmacological inhibition of hERG can lead to the ultimate failure of pre-clinical drug
candidates, it is important to understand the different mechanisms by which hERG function
can be affected.7 Drug-like molecules can bind directly to and inhibit hERG. However, it
has also been demonstrated that Hsp90 inhibitors halt the functional maturation of hERG
and can therefore inhibit hERG function by preventing trafficking to the membrane.11-12
Hsp90 inhibitors appear to prevent the glycosylation of hERG and halt translocation from
the ER to the cell surface, which results in non-functional hERG accumulation in the
cytosol.8 Since small molecule Hsp90 inhibitors are of great interest to the pharmaceutical
industry, it is important to outline the liabilities associated with Hsp90 inhibition. These
results clearly demonstrate that the cardiotoxic liability associated with pan-Hsp90
inhibition may be avoidable by the development of Hsp90 inhibitors that avoid Hsp90α.
In addition, these results suggest that deconvolution of the Hsp90-isoform proteome is
needed in order to more thoroughly understand the consequences of Hsp90 inhibition. It has
been difficult to biochemically distinguish the roles manifested by each Hsp90 isoform due
to the high structural similarity, significant antibody cross reactivity, and the presence of
Hsp90α/β heteromdimers. Furthermore, only a few Hsp90 isoform–dependent client
proteins have been identified. Studies have demonstrated that the cellular inhibitor of
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apoptosis protein 1 (c-IAP1) depends upon Hsp90β,21 while some intermediates in the
major histocompatibility complex (MHC) class I, but not MHC class II, pathway depend
solely upon Hsp90α.22-23 Phenotypic screens have also been used to identify the unique
roles played by each cytosolic Hsp90 isoforms. For example, Hsp90β appears to be critical
for embryonic development, as an Hsp90β null mutation results in embryonic lethality.24
Meanwhile, Hsp90α is overexpressed in many cancer cells and has been linked to cancer
cell invasiveness, which is directly related to matrix metalloproteinase 2 activity.25 Chadli et
al. provided rationale to support Hsp90 isoform dependence of co-chaperones.26 In their
studies, they found the general cell UNC45 (GCUNC45) binds preferentially to Hsp90β and
was capable of stalling the chaperone machinery during the progression/activation of the
progesterone receptor. In this example, the specific co-chaperone required for client protein
activation/folding determines the isoform dependence. In a yeast model system in which the
endogenous Hsp90 was replaced with either hHsp90α or hHsp90β as the sole Hsp90,
differences the activation of client proteins and in the sensitivity to Hsp90 inhibitors were
observed.27-28
In conclusion, we have shown herein that the hERG channel depends solely on Hsp90α,
providing rationale for the design of isoform selective Hsp90 inhibitors. Furthermore,
understanding the responsibilities manifested by each Hsp90 isoform will be crucial to the
development of Hsp90 inhibitors and will allow for the development of Hsp90 inhibitors
that produce fewer adverse effects.
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Hsp90 Heat shock protein 90
hERG human ether-a-gogo-related gene
Grp94 glucose regulated protein 94
Trap1 tumor necrosis factor receptor associated protein1
siRNA small interfering RNA
siRNA short-hairpin RNA
FKBP51 FK506 binding protein 51
CypA Cyclophilin A
TPR tetratricopeptide repeat
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Figure 1. hERG co-immunoprecipitates with Hsp90αand not Hsp90β
Cross-linked cell lysates were immunoprecipitated with an anti-hERG antibody,
immunocomplexes were collected with Protein G beads. Proteins were eluted,
uncrosslinked, separated by SDS-PAGE, and analyzed by Western Blotting (fg = fully
glycosylated; cg = core glycosylated).
Peterson et al. Page 9













Figure 2. Hsp90α knockdown reduces hERG trafficking
A) Control, Hsp90α, and Hsp90β targeted siRNA were transfected into hERG-HEK cells.
The effect of siRNA was analyzed by Western Blot Analysis 48 h. post transfection. Actin
represents a loading control. B) Equation for trafficking efficiency. C) Densitometry
analysis of Western Blots from A (N=3); *, p < 0.02; **, p < 0.01 versus control siRNA
values.
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Figure 3. Hsp90α levels directly affect hERG trafficking efficiency
Western blot analysis of cell lystates from HEK-hERG cells that either express Hsp90α or
Hsp90β targeted shRNA after doxycyline treatment for (A) 24 h. or (B) 48 h. treatment. C)
and D) Densitometry analysis of Western blots from A and B (Hsp90α knockdown)
respectively. E) and F) Densitometry analysis of Western blots from A and B (Hsp90β
knockdown) respectively. Western blot analysis of cell lystates from HEK-hERG cells
expressing G) Hsp90α targeted shRNA or H) Hsp90β targeted shRNA after 48 h.
doxycycline treatment.
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Table 1
hERG interacting proteins (N=3)1.
Protein Accession Number (NCBI) No. Unique Peptides Sequence Coverage (%)
hERG Q12809.1 9 11
Hsp90α P07900 6 22
Hsc70* P11142 13 29
Hsp70 P08107 21 40
Calnexin* P27824 3 7
FKBP51 Q02790 3 12
Hip P50502 2 7
Hop* P31948 6 16
Cyclophilin A P62937 7 47
14-3-3 P62258 9 44
1
Confidence level of 95% or greater
*
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